Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer.

ABSTRACT:

Background

Front-line maintenance therapy with bevacizumab demonstrates high efficacy and safety in epithelial ovarian cancer, as already shown in large phase III trials; however, the corresponding study populations are often not fully representative of patients in clinical routine. In this Austria-based multicenter study, we aimed to explore the real-world outcomes of bevacizumab use in front-line treatment of ovarian cancer, including patients with comorbidities and poor performance status.

Patients

This study is an open label single arm multicenter noninterventional trial and included patients with newly diagnosed advanced epithelial ovarian cancer, who were treated with platinum-based chemotherapy and were candidates for receiving bevacizumab according to the product lab

SUBMITTER: Tsibulak I 

PROVIDER: S-EPMC9606045 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature